Document Detail


Therapy with recombinant growth hormone
MedLine Citation:
PMID:  18062578     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Therapy with recombinant growth hormone is currently approved for the indications growth hormone deficiency,Turner syndrome, chronic renal failure, small for gestational age (SGA) and Prader-Willi syndrome. Positive experience from on-going clinical studies (e.g. on obesity, type 2 diabetes, Crohn's disease) support an extended range of applications for recombinant growth hormone. However, growth hormone therapy is very expensive. On the other hand, biosimilars are already available that are significantly lower in price. During the coming years, research must show whether the efficacy and safety of biosimilars (including possible new indications) are equal to that of the established preparations.
Authors:
Martin Wabitsch
Publication Detail:
Type:  English Abstract; Journal Article    
Journal Detail:
Title:  MMW Fortschritte der Medizin     Volume:  149     ISSN:  1438-3276     ISO Abbreviation:  MMW Fortschr Med     Publication Date:  2007 Jun 
Date Detail:
Created Date:  2007-12-07     Completed Date:  2008-02-06     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100893959     Medline TA:  MMW Fortschr Med     Country:  Germany    
Other Details:
Languages:  ger     Pagination:  41-3     Citation Subset:  IM    
Affiliation:
Sektion Pädiatrische Endokrinologie, Universitätsklinik für Kinder- und Jugendmedizin, Ulm. martin.wabitsch@uniklinik-ulm.de
Vernacular Title:
Wachstumshormon bald auch bei Adipositas und Diabetes?
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Cost Control / trends
Crohn Disease / drug therapy*
Diabetes Mellitus, Type 2 / drug therapy*
Drug Costs / trends
Drugs, Generic / adverse effects,  economics,  therapeutic use
Dwarfism / drug therapy*
Forecasting
Germany
Growth Hormone / adverse effects,  economics,  therapeutic use*
Obesity / drug therapy*
Chemical
Reg. No./Substance:
0/Drugs, Generic; 9002-72-6/Growth Hormone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Systemic therapy of colorectal carcinoma
Next Document:  Na+/Mg2+ antiport in non-erythrocyte vertebrate cells.